These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
242 related articles for article (PubMed ID: 16614245)
21. High-risk childhood acute lymphoblastic leukemia in first remission treated with novel intensive chemotherapy and allogeneic transplantation. Marshall GM; Dalla Pozza L; Sutton R; Ng A; de Groot-Kruseman HA; van der Velden VH; Venn NC; van den Berg H; de Bont ES; Maarten Egeler R; Hoogerbrugge PM; Kaspers GJ; Bierings MB; van der Schoot E; van Dongen J; Law T; Cross S; Mueller H; de Haas V; Haber M; Révész T; Alvaro F; Suppiah R; Norris MD; Pieters R Leukemia; 2013 Jul; 27(7):1497-503. PubMed ID: 23407458 [TBL] [Abstract][Full Text] [Related]
22. Randomized post-induction and delayed intensification therapy in high-risk pediatric acute lymphoblastic leukemia: long-term results of the international AIEOP-BFM ALL 2000 trial. Attarbaschi A; Mann G; Zimmermann M; Bader P; Barisone E; Basso G; Biondi A; Cario G; Cazzaniga G; Colombini A; Flotho C; Kuhlen M; Lang P; Lauten M; Linderkamp C; Locatelli F; Lo Nigro L; Möricke A; Niggli F; Panzer-Grümayer R; Parasole R; Peters C; Caterina Putti M; Rizzari C; Suttorp M; Valsecchi MG; Conter V; Schrappe M; Leukemia; 2020 Jun; 34(6):1694-1700. PubMed ID: 31806872 [No Abstract] [Full Text] [Related]
23. NOTCH1 pathway activating mutations and clonal evolution in pediatric T-cell acute lymphoblastic leukemia. Kimura S; Seki M; Yoshida K; Shiraishi Y; Akiyama M; Koh K; Imamura T; Manabe A; Hayashi Y; Kobayashi M; Oka A; Miyano S; Ogawa S; Takita J Cancer Sci; 2019 Feb; 110(2):784-794. PubMed ID: 30387229 [TBL] [Abstract][Full Text] [Related]
24. The treatment of childhood acute lymphoblastic leukemia in Guatemala: Biologic features, treatment hurdles, and results. Antillón FG; Blanco JG; Valverde PD; Castellanos M; Garrido CP; Girón V; Letona TR; Osorio EJ; Borrayo DA; Mack RA; Melgar MA; Lorenzana R; Ribeiro RC; Metzger M; Conter V; Rossi E; Valsecchi MG Cancer; 2017 Feb; 123(3):436-448. PubMed ID: 27683100 [TBL] [Abstract][Full Text] [Related]
25. Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial. Millot F; Suciu S; Philippe N; Benoit Y; Mazingue F; Uyttebroeck A; Lutz P; Mechinaud F; Robert A; Boutard P; Marguerite G; Ferster A; Plouvier E; Rialland X; Behard C; Plantaz D; Dresse MF; Philippet P; Norton L; Thyss A; Dastugue N; Waterkeyn C; Vilmer E; Otten J; J Clin Oncol; 2001 Apr; 19(7):1935-42. PubMed ID: 11283125 [TBL] [Abstract][Full Text] [Related]
26. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Conter V; Bartram CR; Valsecchi MG; Schrauder A; Panzer-Grümayer R; Möricke A; Aricò M; Zimmermann M; Mann G; De Rossi G; Stanulla M; Locatelli F; Basso G; Niggli F; Barisone E; Henze G; Ludwig WD; Haas OA; Cazzaniga G; Koehler R; Silvestri D; Bradtke J; Parasole R; Beier R; van Dongen JJ; Biondi A; Schrappe M Blood; 2010 Apr; 115(16):3206-14. PubMed ID: 20154213 [TBL] [Abstract][Full Text] [Related]
27. Effectiveness of rubidomycin in induction therapy with vincristine, prednisone, and L-asparaginase for standard risk childhood acute lymphocytic leukemia: results of a Dutch phase III study (ALL V). A report on behalf of the Dutch Childhood Leukemia Study Group (DCLSG). van der Does-van den Berg A; van Wering ER; Suciu S; Solbu G; van 't Veer MB; Rammeloo JA; de Koning J; van Zanen GE Am J Pediatr Hematol Oncol; 1989; 11(2):125-33. PubMed ID: 2665546 [TBL] [Abstract][Full Text] [Related]
28. [Acute lymphoblastic leukemia in children with initial leucocytosis above 50,000/mm3: summary of treatment results of Polish Pediatric Leukemia/Lymphoma Study Group]. Skoczeń S; Balwierz W; Moryl-Bujakowska A; Pawińska K; Luszczyńska A; Balcerska A; Płoszyńska A; Chybicka A; Dobaczewski G; Juszczak K; Wachowiak J; Derwich K; Kowalczyk J; Wiśniewska-Slusarz H; Matysiak M; Krauze A; Pawelec K; Sońta-Jakimczyk D; Tomaszewska R; Wysocki M; Styczyńskii J; Swiatkiewicz V; Przegl Lek; 2006; 63(1):11-4. PubMed ID: 16892892 [TBL] [Abstract][Full Text] [Related]
29. Overexpression of BCL2 and BAX following BFM induction therapy predicts ch-ALL patients' poor response to treatment and short-term relapse. Stamati L; Avgeris M; Kosmidis H; Baka M; Anastasiou T; Piatopoulou D; Scorilas A; Gourgiotis D J Cancer Res Clin Oncol; 2015 Nov; 141(11):2023-36. PubMed ID: 25982455 [TBL] [Abstract][Full Text] [Related]
30. NOTCH1 and FBXW7 mutations favor better outcome in pediatric South Indian T-cell acute lymphoblastic leukemia. Natarajan V; Bandapalli OR; Rajkumar T; Sagar TG; Karunakaran N J Pediatr Hematol Oncol; 2015 Jan; 37(1):e23-30. PubMed ID: 25493453 [TBL] [Abstract][Full Text] [Related]
31. No advantage of a rotational continuation phase in acute lymphoblastic leukemia in childhood treated with a BFM back-bone therapy. Felice MS; Rossi JG; Gallego MS; Alfaro EM; Zubizarreta PA; Fraquelli LE; Alonso CN; Guitter MR; Scopinaro MJ Pediatr Blood Cancer; 2011 Jul; 57(1):47-55. PubMed ID: 21394895 [TBL] [Abstract][Full Text] [Related]
32. [The prospects for children with acute lymphoblastic leukemia of being cured has increased in the Czech Republic in the 21st century to 90% - outcome of the ALL-IC BFM 2002 trial]. Zdráhalová K; Štěrba J; Domanský J; Blažek B; Ptoszková H; Mihál V; Novák Z; Hak J; Procházková D; Černá Z; Timr P; Jabali Y; Sedláček P; Smíšek P; Zemanová Z; Jarošová M; Houdková A; Mejstříková E; Hrušák O; Zuna J; Janotová I; Trka J; Starý J Cas Lek Cesk; 2015; 154(2):79-89. PubMed ID: 25994910 [TBL] [Abstract][Full Text] [Related]
33. Thromboembolic events in children with acute lymphoblastic leukemia (BFM protocols): prednisone versus dexamethasone administration. Nowak-Göttl U; Ahlke E; Fleischhack G; Schwabe D; Schobess R; Schumann C; Junker R Blood; 2003 Apr; 101(7):2529-33. PubMed ID: 12517808 [TBL] [Abstract][Full Text] [Related]
35. Treatment of patients with acute lymphoblastic leukemia with bulky extramedullary disease and T-cell phenotype or other poor prognostic features: randomized controlled trial from the Children's Cancer Group. Steinherz PG; Gaynon PS; Breneman JC; Cherlow JM; Grossman NJ; Kersey JH; Johnstone HS; Sather HN; Trigg ME; Uckun FM; Bleyer WA Cancer; 1998 Feb; 82(3):600-12. PubMed ID: 9452280 [TBL] [Abstract][Full Text] [Related]
36. High VLA-4 expression is associated with adverse outcome and distinct gene expression changes in childhood B-cell precursor acute lymphoblastic leukemia at first relapse. Shalapour S; Hof J; Kirschner-Schwabe R; Bastian L; Eckert C; Prada J; Henze G; von Stackelberg A; Seeger K Haematologica; 2011 Nov; 96(11):1627-35. PubMed ID: 21828124 [TBL] [Abstract][Full Text] [Related]
37. Methodological aspects of minimal residual disease assessment by flow cytometry in acute lymphoblastic leukemia: A French multicenter study. Fossat C; Roussel M; Arnoux I; Asnafi V; Brouzes C; Garnache-Ottou F; Jacob MC; Kuhlein E; Macintyre-Davi E; Plesa A; Robillard N; Tkaczuk J; Ifrah N; Dombret H; Béné MC; Baruchel A; Garand R; Cytometry B Clin Cytom; 2015 Jan; 88(1):21-9. PubMed ID: 25363877 [TBL] [Abstract][Full Text] [Related]
38. Incidence and clinical outcome of children with BCR/ABL-positive acute lymphoblastic leukemia (ALL). A prospective RT-PCR study based on 673 patients enrolled in the German pediatric multicenter therapy trials ALL-BFM-90 and CoALL-05-92. Schlieben S; Borkhardt A; Reinisch I; Ritterbach J; Janssen JW; Ratei R; Schrappe M; Repp R; Zimmermann M; Kabisch H; Janka-Schaub G; Bartram CR; Ludwig WD; Riehm H; Lampert F; Harbott J Leukemia; 1996 Jun; 10(6):957-63. PubMed ID: 8667652 [TBL] [Abstract][Full Text] [Related]
39. Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Münster-based intensive chemotherapy. The Associazione Italiana di Ematologia ed Oncologia Pediatrica. Conter V; Aricò M; Valsecchi MG; Rizzari C; Testi AM; Messina C; Mori PG; Miniero R; Colella R; Basso G J Clin Oncol; 1995 Oct; 13(10):2497-502. PubMed ID: 7595699 [TBL] [Abstract][Full Text] [Related]
40. Early T-cell precursor acute lymphoblastic leukaemia in children treated in AIEOP centres with AIEOP-BFM protocols: a retrospective analysis. Conter V; Valsecchi MG; Buldini B; Parasole R; Locatelli F; Colombini A; Rizzari C; Putti MC; Barisone E; Lo Nigro L; Santoro N; Ziino O; Pession A; Testi AM; Micalizzi C; Casale F; Pierani P; Cesaro S; Cellini M; Silvestri D; Cazzaniga G; Biondi A; Basso G Lancet Haematol; 2016 Feb; 3(2):e80-6. PubMed ID: 26853647 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]